Study of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

September 4, 2020 updated by: C. R. Bard

A Post-Market, Prospective, Multi-Center, Single-Arm Clinical Investigation of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

The purpose of this study is to collect additional data on safety and performance of Phasix™ Mesh in subjects requiring Ventral Hernia Working Group (VHWG) Grade 3 midline hernia repair.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Approximately 85 subjects, at approximately 12 sites across Europe will be enrolled and treated to study the use of Phasix™ Mesh. All treated subjects will be followed for 2 years post-implantation.

Study Type

Interventional

Enrollment (Actual)

84

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Vienna, Austria
        • Wilhelminenspital
      • Bonheiden, Belgium
        • Imelda Ziekenhuis
      • Gent, Belgium
        • UZ Gent
      • Leuven, Belgium
        • UZ Leuven (Gasthuisberg)
      • Copenhagen, Denmark
        • Bispebjerg Hospital
      • Lille, France
        • Centre Hospitalier Régional Universitaire de Lille
      • Paris, France
        • APHP Hôpital Cochin
      • Berlin, Germany
        • Vivantes Hospital
      • Frankfurt, Germany
        • Klinikum der Johann Wolfgang Goethe-Universität
    • Brandenburg
      • Cottbus, Brandenburg, Germany
        • Day Surgery and Hernia Center
      • Roma, Italy
        • Policlinico Umberto I
      • Capelle Aan Den IJssel, Netherlands
        • IJsselland Ziekenhuis
      • Helmond, Netherlands
        • Elkerliek Ziekenhuis
      • Zwolle, Netherlands
        • Isala
      • London, United Kingdom
        • University College London Hospitals NHS Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subject must be diagnosed with incisional midline hernia.
  • Subject has a VHWG Grade 3 hernia (as defined in the protocol).
  • Size of hernia ≥ 10 cm2.
  • Subject must be willing to undergo a planned retro-rectus hernia repair (onlay allowed as an exception when retro-rectus placement cannot be achieved; using absorbable suture) with or without Component Separation Technique.

Exclusion Criteria:

  • Subject with > 4 previous repairs of the hernia under observation.
  • Body Mass Index (BMI) > 35 kg/m2.
  • The subject is on, or suspected to be placed on, chemotherapy medications during any part of the study.
  • The subject has peritonitis.
  • Known human immunodeficiency virus (HIV) infection (if documented in the subject's record).
  • The subject has cirrhosis of the liver and/or ascites.
  • Subject is American Society of Anesthesiology Class 4 or 5.
  • Complete removal of existing mesh from a prior hernia repair (in the same affected area) is not possible.
  • The hernia repair requires more than a single piece mesh (with adequate overlap beyond the margins of the defect on all sides).
  • Subject has intact permanent mesh adjacent to the current hernia to be repaired.
  • Subject's hernia repair requires intraabdominal mesh placement.
  • Surgical technique requires surgical bridge repair as the sole repair.
  • Subject has any condition that, in the opinion of the Investigator, would preclude the use of the study device, or preclude the subject from completing the follow-up requirements.
  • Subject is pregnant or has plans to become pregnant during the study period or is currently breastfeeding.
  • Subject has an alcohol/substance abuse problem or has had a relapse within 12 months of the screening visit.
  • Subject was involved in another interventional clinical study in the last 30 days prior to Informed Consent Form (ICF) signature.
  • Subject is part of the site personnel directly involved with this study.
  • Subject has a life expectancy of less than 2 years at the time of enrollment.
  • Subject has a known sensitivity to Phasix™ Mesh or component materials (patients with known allergies to tetracycline hydrochloride or kanamycin sulfate should be avoided).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Phasix™ Mesh
Patients treated with Phasix™ Mesh for hernia repair
A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With One or More Surgical Site Occurrence Within 3 Months of Index Procedure
Time Frame: 3 Months
Proportions of subjects with Surgical Site Occurrences, which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 3 months. For analysis purposes, the aggregate Surgical Site Occurrence is defined as follows: "The question <Is there any evidence of surgical site occurrence (SSO) in the same location as the index procedure?> is answered with <yes>
3 Months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With One or More Surgical Site Occurrence Within 24 Months of Index Procedure
Time Frame: 24 Months
Proportions of subjects with Surgical Site Occurrences, which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 3 months. For analysis purposes, the aggregate Surgical Site Occurrence is defined as follows: "The question <Is there any evidence of surgical site occurrence (SSO) in the same location as the index procedure?> is answered with <yes> "
24 Months
Number of Participants With a Hernia Recurrence
Time Frame: 24 Months
Proportion of subjects with hernia recurrence. Hernia recurrence rates will be assessed by physical examination (or if standard of care via CT/MRI or ultrasonography) at each study visit through 24 months. A recurrent hernia will be defined as any hernia identified or confirmed by the investigator, during any study follow-up visit, in approximately the same position as the hernia repaired in the study procedure.
24 Months
Number of Participants With One or More Surgical Site Infection
Time Frame: 24 Months
Proportion of subjects with surgical site infections. Infections at the surgical site will be assessed by physical examination at each study visit through 24 months. If an infection is suspected, a routine culture, obtained via each site's standard protocol, should be obtained to determine cell count and type (i.e. yeast, gram positive or gram negative bacteria, or other). If genus and species of the culture are identified as part of the routine practice at the site, that information should be recorded. Classification will follow the US Centers of Disease Control and Prevention (CDC) guidelines for superficial, deep and organ/space surgical site infections.
24 Months
Mean Change in Pain Between Baseline (Pre-Index Procedure) and 24 Months Post-Index Procedure, as Measured by a 10.0 cm Visual Analogue Scale
Time Frame: 24 Months
Mean change in self-reported pain measured on a Visual Analog Scale between Baseline and 24-month follow up. Scores are measured on a 10.0 cm line, lower values correspond with low pain perception. The outcome measure is presented as the absolute difference between the pain perception at Baseline and the pain perception at 24-month follow up. A negative score means a decrease in pain perception.
24 Months
Number of Participants With One or More Device-related Adverse Event
Time Frame: 24 Months
Incidence Device-related Adverse Events: number of subjects with one or more possibly or definitely device-related Adverse Event.
24 Months
Number of Participants Requiring Reoperation Due to Index Hernia Repair
Time Frame: 24 Months
Rate of reoperation due to the index hernia repair: the proportion of subjects with post-procedure reoperation due to the index hernia repair.
24 Months
Mean Patient Reported Outcomes on Quality of Life Parameters as Measured by the Carolinas Comfort Scale (CCS) at 1, 3, 12 and 24 Months Post-Index Procedure
Time Frame: 24 Months

Each scale score (sensation of mesh, pain or movement limitations) ranges from 0-5 and is the average across the domains. The Total CCS Score ranges from 0-5 and is the average of the 3 scale scores. Low scores represent fewer symptoms or difficulties.

Absolute values of the Total CCS Score at 1-Month follow-up, at 3-Month follow-up, at 12-Month follow-up and at 24-Month follow up are reported.

The absolute value at Baseline, or a change in self-reported quality of life measured by Carolinas Comfort Scale® cannot be reported, as subjects had incorrectly answered the questions on Sensation of Mesh at Baseline where no Phasix Mesh was yet implanted, thereby creating a bias in the results.

24 Months
Mean Change in Quality of Life Assessments as Measured by the EQ-5D Between Baseline (Pre-Index Procedure) and 24 Months Post-Index Procedure
Time Frame: 24 Months
Change in self-reported quality of life measured by EuroQol-5 Dimensions (EQ-5D™). Each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) has 3 levels (no problems, some problems and extreme problems). The data is converted into a summary index number between 0 and 1, whereby 1 corresponds with the highest perception of Quality of Life. The outcome measure reports the absolute change from Baseline until 24-months follow up. A positive value corresponds with an increase in Quality of Life.
24 Months
Mean Surgical Procedure Time of the Index Procedure as Measured From Incision to Closure
Time Frame: 1 day
Surgical procedure time as measured from incision to closure (skin to skin)
1 day
Mean Time Until Participants Were Able to Return to Work
Time Frame: 24 Months
The number of days until subject returned to work, calculated as the date when employed subjects were able to fully get back to work minus the date of surgery.
24 Months
Mean Length of Hospital Stay Related to Index Procedure
Time Frame: 1 Month
The length of hospital stay for the index procedure is calculated as the date of hospital discharge minus the date of hospital admission. Days in intensive care unit, days in step down unit (medium care) and days in the ward will be summarized as well.
1 Month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Hans Jeekel, Erasmus University Medical Centre Rotterdam

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 23, 2016

Primary Completion (Actual)

July 31, 2017

Study Completion (Actual)

June 20, 2019

Study Registration Dates

First Submitted

February 11, 2016

First Submitted That Met QC Criteria

March 24, 2016

First Posted (Estimate)

March 25, 2016

Study Record Updates

Last Update Posted (Actual)

September 25, 2020

Last Update Submitted That Met QC Criteria

September 4, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hernia

Clinical Trials on Phasix™ Mesh

Subscribe